On Tuesday, Shares of Palo Alto Networks, Inc. (NYSE:PANW), gained 5.36% to $154.37.
Palo Alto Networks, declared its enterprise security platform has received a superior security score in the NSS Labs 2015 Next-Generation Intrusion Prevention System (NGIPS) test.
The test comprises a mixture of both real-world and lab-based evaluations and assists organizations assess how a security offering performs in the face of multiple exploits and evasion techniques. The Palo Alto Networks platform achieved the highest security efficacy ratings of any other offering tested when exposed to live (real-time) drive-by exploits. Detailed test results comprise:
- 100% block rate for all live (real-time) web-based exploits being used by Threat Actors in active campaigns during the course of the test. These exploits target vulnerable client applications and then silently download and install malware, and are also known as drive-by exploits
- 100% effectiveness rating for all evasions techniques tested
- 8% overall block rate, counting both exploits from NSS’ extensive library of attacker and target-initiated exploits, in addition to live web-based exploits being used by Threat Actors in active campaigns during the course of the test.
Palo Alto Networks, Inc. provides enterprise security platform to enterprises, service providers, and government entities worldwide. Its platform comprises Next-Generation Firewall that delivers application, user, and content visibility and control, in addition to protection against network-based cyber threats; and Threat Intelligence Cloud that offers central intelligence capabilities, in addition to automated delivery of preventative measures against cyber attacks.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), gained 5.30% to $132.20, during its last trading session.
Bernstein analyst said Gilead should “pull the trigger” on a deal with Vertex.
“No company in our coverage or industry has such an abundance of cash, and simultaneously such clear cut need for externally attained drug revenue as Gilead Sciences,” wrote Bernstein’s Geoffrey Porges in a note to clients, citing what he anticipates to be the “inevitable simultaneous decline” of the company’s two key drug franchises for treating HIV and Hepatitis C.
Mr. Porges said that Gilead should address the threats to its franchises by buying up a companies this year with the “promise or high probability of an incremental $5-%7 billion in revenue.” Based on the premiums that recent biotech deals have fetched, Gilead will need to pay between $38 billion and $45 billion by his estimates to get a drug with $7 billion in revenue potential, he said.
He calls Vertex the most promising target because it’s one of the few independent assets of size in the pharma space. Moreover, Vertex’s entire franchise is focused on treating cystic fibrosis, where Gilead has a product and commercial infrastructure that would allow it to find synergies, he wrote.
Vertex shareholders may be willing to entertain an offer now because there are concerns that Vertex has pursued an “all-eggs-in-one-basket” strategy, he posits.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
At the end of Tuesday’s trade, Shares of Omnicare Inc. (NYSE:OCR), gained 5.23% to $81.07, hitting its highest level.
Omnicare, will release its financial results for the first quarter of fiscal 2015 before the market opens on Wednesday, April 29, 2015. Omnicare will hold its quarterly conference call to talk about first-quarter results on Wednesday, April 29, at 9:00 a.m. ET.
Omnicare, Inc. operates as a healthcare services company that specializes in the administration of pharmaceutical care in the United States. The company’s Long-Term Care Group segment offers pharmaceuticals, and related pharmacy and ancillary services to long-term care facilities; and chronic care facilities and other settings.
Finally, STMicroelectronics NV (NYSE:STM), ended its last trade with 4.78% gain, and closed at $9.65.
STMicroelectronics, declared new members in its multi-core microcontroller (MCU) family aimed at making cars safer. These new devices are the first to be launched with ST’s proprietary in-house 40nm embedded Flash process.
The new automotive MCUs combine compliance with the most stringent automotive safety standards, encryption for security, and raised memory size for the storage of vital programs and data, strengthening ST’s product line of fault-tolerant microcontrollers for demanding applications throughout the car. These mission-critical applications comprise engine administration, transmission, anti-lock braking, electric power steering, active suspension, and advanced driver assistance systems (ADAS).
Part of ST’s Power Architecture(TM) single-chip 32-bit automotive-MCU family, the SPC58NE product line combines multiple high-performance dual-issue cores with up to 6MB Flash and 768kB internal RAM memory, eight CAN (Controller Area Network) interfaces, and an optimized peripheral set based on the end application. The multiple cores ensure redundancy in these most-important applications to meet the safety and security demands of vehicle manufacturers-and consumers.
The SPC58NE product line is presently accessible in BGA 292 and LQFP176 package configurations. KGD versions are also planned in the near future. Compliant with the ISO 26262 ASIL-D and EVITA Medium class, the SPC58NE84 is sampling now. For further information, counting pricing, please contact your ST sales office.
STMicroelectronics N.V. designs, develops, manufactures, and markets various semiconductor integrated circuits and discrete devices worldwide. From energy administration and savings to trust and data security, from healthcare and wellness to smart consumer devices, in the home, car and office, at work and at play, ST is found everywhere microelectronics make a positive and innovative contribution to people’s life. By getting more from technology to get more from life, ST stands for life augmented.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
